Updates on STK-001: A Possible Disease-Modifying Therapy for Dravet Syndrome
There have been some exciting data releases from Stoke Therapeutics regarding their Phase 1/2a trial for the investigational therapy, STK-001, that suggest this could be the first truly disease-modifying therapy for Dravet syndrome. Results indicate significant reductions in seizure frequency and notable improvements in measures related to behavior and cognition. In addition to a recent […]
Updates on STK-001: A Possible Disease-Modifying Therapy for Dravet Syndrome Read More »